))
Keeping Pace in Lung Cancer - HER2: Unveiling New Horizons in NSCLC Treatment
Manage episode 433877620 series 3381434
Innhold levert av ReachMD. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av ReachMD eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.
CME credits: 0.25
Valid until: 15-11-2024
Claim your CME credit at https://reachmd.com/programs/cme/keeping-pace-in-lung-cancer-her2-unveiling-new-horizons-in-nsclc-treatment/16083/
We now have an FDA-approved targeted therapy to treat HER2-mutated NSCLC. Drs. Aggarwal and Sands discuss the most current clinical data, including management of adverse events.=
…
continue reading
Valid until: 15-11-2024
Claim your CME credit at https://reachmd.com/programs/cme/keeping-pace-in-lung-cancer-her2-unveiling-new-horizons-in-nsclc-treatment/16083/
We now have an FDA-approved targeted therapy to treat HER2-mutated NSCLC. Drs. Aggarwal and Sands discuss the most current clinical data, including management of adverse events.=
578 episoder
Del
